Two IPOs are scheduled to raise $1.3 billion in the week ahead. While the IPO calendar is relatively quiet at the moment, several issuers could launch, including pool equipment supplier Hayward Holdings (HAYW) and crafts-focused...read more
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. The IPO pipeline remained active as well, with 3 IPOs and 38 SPACs submitting initial filings. ...read more
Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, raised $230 million by offering 11.5 million shares at $20, above the upwardly revised range of $18 to $19. The company offered 1 million more shares than anticipated. It...read more
Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise $194 million by offering 10.5 million shares at...read more
US IPO Week Ahead: Health insurer Oscar Health leads a 2 IPO week
Two IPOs are scheduled to raise $1.3 billion in the week ahead. While the IPO calendar is relatively quiet at the moment, several issuers could launch, including pool equipment supplier Hayward Holdings (HAYW) and crafts-focused...read more
US IPO Weekly Recap: Biotechs flood the IPO market in a 14 IPO week
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. The IPO pipeline remained active as well, with 3 IPOs and 38 SPACs submitting initial filings. ...read more
Solid tumor biotech Bolt Biotherapeutics prices further upsized IPO at $20, above the upwardly revised range
Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, raised $230 million by offering 11.5 million shares at $20, above the upwardly revised range of $18 to $19. The company offered 1 million more shares than anticipated. It...read more
Solid tumor biotech Bolt Biotherapeutics increases deal size by 29% ahead of $194 million IPO
Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise $194 million by offering 10.5 million shares at...read more